Abstract
The explanation of the mechanisms underlying the pathogenesis of rheumatoid arthritis (RA), along with the development of a wide range of biologics (bDMARDs), is among the major achievements of medicine in the 21st century. A new direction in the pharmacotherapy of inflammatory rheumatic diseases is associated with the development of “targeted” oral anti-inflammatory drugs, which include Janus kinase (JAK) inhibitors. One representative of the class of JAK inhibitors is upadacitinib (UPA), which has been registered for the treatment of RA and is undergoing clinical studies in patients with ankylosing spondylitis, psoriatic arthritis, and other inflammatory rheumatic diseases. This review presents new data on the efficacy and safety of UPA in RA.
Highlights
Расшифровка механизмов патогенеза ревматоидного артрита в сочетании с разработкой широкого спектра генно-инженерных биологических препаратов относятся к числу крупных достижений медицины XXI в
The explanation of the mechanisms underlying the pathogenesis of rheumatoid arthritis (RA), along with the development of a wide range of biologics, is among the major achievements of medicine in the 21st century
A new direction in the pharmacotherapy of inflammatory rheumatic diseases is associated with the development of “targeted” oral anti-inflammatory drugs, which include Janus kinase (JAK) inhibitors
Summary
Представителем класса этих ингибиторов является упадацитиниб, который зарегистрирован для лечения ревматоидного артрита и проходит клинические испытания при анкилозирующем спондилите, псориатическом артрите и других иммуновоспалительных ревматических заболеваниях. One representative of the class of JAK inhibitors is upadacitinib (UPA), which has been registered for the treatment of RA and is undergoing clinical studies in patients with ankylosing spondylitis, psoriatic arthritis, and other inflammatory rheumatic diseases. For citation: Nasonov E.L., Lila A.M. The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases. Наряду с тофацитинибом (ТОФА) [5, 6] и барицитинибом (БАРИ) [7, 8] недавно для лечения РА зарегистрирован новый ингибитор JAK – упадацитиниб (УПА) [9, 10], обсуждение перспектив применения которого в ревматологии является целью нашего обзора. Общая характеристика УПА в сравнении с ТОФА и БАРИ представлена в таблице 1
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
